Recent Updates
Recently added Catalysts

Osteoarthritis Knee Pain: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.1Buniverse median $1.20B
Allocated capital$265M$1.1B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank243/299crowding rank 246

Osteoarthritis Knee Pain is uncontested. Pacira Biosciences (PCRX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Enekinragene Inzadenovec in phase 2.

There is no public comparable to price it against. PCRX spreads its $1.1B market cap across 4 indications, so $265M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$265M of allocated capital sits in Osteoarthritis Knee Pain, ranking it 243rd of 299 indications by the money committed to it.

Companies developing drugs for Osteoarthritis Knee Pain 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PCRXPacira BiosciencesEnekinragene InzadenovecPhase 22$1.1BNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Osteoarthritis Knee Pain counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Osteoarthritis Knee Pain has one competitor and a median of $1.1B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Acute Postoperative Pain1 company · $265M · median $1.1BUncontestedPostoperative Pain1 company · $265M · median $1.1BUncontestedCervical Spinal Cord Injury1 company · $278M · median $278MUncontestedMigraine1 company · $218M · median $436MUncontestedPrimary Erythromelalgia1 company · $342M · median $2.4BUncontestedPsychosis in Alzheimer's Disease1 company · $187M · median $560MUncontestedMajor Depressive Episode1 company · $426M · median $1.3BUncontestedRelapsing Remitting Multiple Sclerosis1 company · $87M · median $174MUncontested

Osteoarthritis Knee Pain pipeline questions

Which biotech companies are developing drugs for Osteoarthritis Knee Pain?

Pacira Biosciences (PCRX, Enekinragene Inzadenovec, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Osteoarthritis Knee Pain.

How advanced is the Osteoarthritis Knee Pain pipeline?

Of the 1 clinical-stage programme in Osteoarthritis Knee Pain, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Osteoarthritis Knee Pain?

No. PCRX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Osteoarthritis Knee Pain, which is why the indication is classified as uncontested.

When is the next Osteoarthritis Knee Pain catalyst?

The next dated catalyst in Osteoarthritis Knee Pain is PCRX on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map